Research programme: psoriasis therapeutic - BioLineRxAlternative Names: BL-7020
Latest Information Update: 26 Mar 2013
At a glance
- Originator BioRap; The Tel Aviv Sourasky Medical Center
- Developer BioLineRx
- Class Recombinant proteins
- Mechanism of Action Keratinocyte modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Psoriasis
Most Recent Events
- 01 Mar 2013 Discontinued - Preclinical for Psoriasis in Israel (unspecified route)